Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells

Bacillus Calmette-Guérin (BCG) confers heterologous immune protection against viral infections and has been proposed as vaccine against SARS-CoV-2 (SCV2). Here, we tested intravenous BCG vaccination against COVID-19 using the golden Syrian hamster model. BCG vaccination conferred a modest reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Alok K., Wang, Rulin, Lombardo, Kara A., Praharaj, Monali, Bullen, C. Korin, Um, Peter, Gupta, Manish, Srikrishna, Geetha, Davis, Stephanie, Komm, Oliver, Illei, Peter B., Ordonez, Alvaro A., Bahr, Melissa, Huang, Joy, Gupta, Anuj, Psoter, Kevin J., Creisher, Patrick S., Li, Maggie, Pekosz, Andrew, Klein, Sabra L., Jain, Sanjay K., Bivalacqua, Trinity J., Yegnasubramanian, Srinivasan, Bishai, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477068/
https://www.ncbi.nlm.nih.gov/pubmed/37674985
http://dx.doi.org/10.1016/j.isci.2023.107733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477068/
https://www.ncbi.nlm.nih.gov/pubmed/37674985
http://dx.doi.org/10.1016/j.isci.2023.107733

Ejemplares similares